Cargando…

Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan

We reported 25 recipients (14 females and 11 males) aged from 18 to 65 years who unexpectedly received a primary dose of undiluted BNT162b2 vaccine (180 μg). The most common adverse reactions included injection site pain (n = 22), followed by fever (9), fatigue (8), chest tightness (6), and dizzines...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheng, Wang-Huei, Wang, Chung-Cheng, Chu, Ching-Chi, Lin, Yueh-Juh, Chang, Sui-Yuan, Ieong, Si-Man, Chang, Shan-Chwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Formosan Medical Association. Published by Elsevier Taiwan LLC. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375841/
https://www.ncbi.nlm.nih.gov/pubmed/35977867
http://dx.doi.org/10.1016/j.jfma.2022.07.009
_version_ 1784768042284089344
author Sheng, Wang-Huei
Wang, Chung-Cheng
Chu, Ching-Chi
Lin, Yueh-Juh
Chang, Sui-Yuan
Ieong, Si-Man
Chang, Shan-Chwen
author_facet Sheng, Wang-Huei
Wang, Chung-Cheng
Chu, Ching-Chi
Lin, Yueh-Juh
Chang, Sui-Yuan
Ieong, Si-Man
Chang, Shan-Chwen
author_sort Sheng, Wang-Huei
collection PubMed
description We reported 25 recipients (14 females and 11 males) aged from 18 to 65 years who unexpectedly received a primary dose of undiluted BNT162b2 vaccine (180 μg). The most common adverse reactions included injection site pain (n = 22), followed by fever (9), fatigue (8), chest tightness (6), and dizziness (6). The most common laboratory abnormalities were anemia (n = 4) and elevated liver transaminase level (4), followed by abnormal leukocyte counts (3) and elevated D-dimer level (3). The adverse reactions and laboratory abnormalities of these recipients were mild and spontaneously recovered within a few weeks. Significant elevations of anti-SARS-CoV-2 spike IgG titers after a booster dose of the BNT162b2 were found. Similar to reports of BNT162b2 clinical trials, the adverse reactions and laboratory abnormalities of these recipients were mild, and they spontaneously recovered within a few weeks. These results provide clinical and immunological effects of undiluted BNT162b2 vaccine inoculation.
format Online
Article
Text
id pubmed-9375841
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Formosan Medical Association. Published by Elsevier Taiwan LLC.
record_format MEDLINE/PubMed
spelling pubmed-93758412022-08-15 Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan Sheng, Wang-Huei Wang, Chung-Cheng Chu, Ching-Chi Lin, Yueh-Juh Chang, Sui-Yuan Ieong, Si-Man Chang, Shan-Chwen J Formos Med Assoc Short Communication We reported 25 recipients (14 females and 11 males) aged from 18 to 65 years who unexpectedly received a primary dose of undiluted BNT162b2 vaccine (180 μg). The most common adverse reactions included injection site pain (n = 22), followed by fever (9), fatigue (8), chest tightness (6), and dizziness (6). The most common laboratory abnormalities were anemia (n = 4) and elevated liver transaminase level (4), followed by abnormal leukocyte counts (3) and elevated D-dimer level (3). The adverse reactions and laboratory abnormalities of these recipients were mild and spontaneously recovered within a few weeks. Significant elevations of anti-SARS-CoV-2 spike IgG titers after a booster dose of the BNT162b2 were found. Similar to reports of BNT162b2 clinical trials, the adverse reactions and laboratory abnormalities of these recipients were mild, and they spontaneously recovered within a few weeks. These results provide clinical and immunological effects of undiluted BNT162b2 vaccine inoculation. Formosan Medical Association. Published by Elsevier Taiwan LLC. 2023-01 2022-08-14 /pmc/articles/PMC9375841/ /pubmed/35977867 http://dx.doi.org/10.1016/j.jfma.2022.07.009 Text en © 2022 Formosan Medical Association. Published by Elsevier Taiwan LLC. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Sheng, Wang-Huei
Wang, Chung-Cheng
Chu, Ching-Chi
Lin, Yueh-Juh
Chang, Sui-Yuan
Ieong, Si-Man
Chang, Shan-Chwen
Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan
title Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan
title_full Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan
title_fullStr Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan
title_full_unstemmed Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan
title_short Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan
title_sort safety and antibody response of recipients who unexpectedly received undiluted prime dose of bnt162b2 covid-19 vaccine in taiwan
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375841/
https://www.ncbi.nlm.nih.gov/pubmed/35977867
http://dx.doi.org/10.1016/j.jfma.2022.07.009
work_keys_str_mv AT shengwanghuei safetyandantibodyresponseofrecipientswhounexpectedlyreceivedundilutedprimedoseofbnt162b2covid19vaccineintaiwan
AT wangchungcheng safetyandantibodyresponseofrecipientswhounexpectedlyreceivedundilutedprimedoseofbnt162b2covid19vaccineintaiwan
AT chuchingchi safetyandantibodyresponseofrecipientswhounexpectedlyreceivedundilutedprimedoseofbnt162b2covid19vaccineintaiwan
AT linyuehjuh safetyandantibodyresponseofrecipientswhounexpectedlyreceivedundilutedprimedoseofbnt162b2covid19vaccineintaiwan
AT changsuiyuan safetyandantibodyresponseofrecipientswhounexpectedlyreceivedundilutedprimedoseofbnt162b2covid19vaccineintaiwan
AT ieongsiman safetyandantibodyresponseofrecipientswhounexpectedlyreceivedundilutedprimedoseofbnt162b2covid19vaccineintaiwan
AT changshanchwen safetyandantibodyresponseofrecipientswhounexpectedlyreceivedundilutedprimedoseofbnt162b2covid19vaccineintaiwan